Publications by authors named "O Colin"
Introduction/aims: Neurolymphomatosis is a hematological condition defined by the direct infiltration of malignant lymphomatous cells into the peripheral nervous system. Since nerve conduction studies may disclose demyelinating features, clinicians may misdiagnose neurolymphomatosis as chronic inflammatory demyelinating polyneuropathy (CIDP). This study aimed to determine whether patients with neurolymphomatosis met the 2021 revised criteria for CIDP.
View Article and Find Full Text PDFUsing proton-proton collision data corresponding to an integrated luminosity of collected by the CMS experiment at , the decay is observed for the first time, with a statistical significance exceeding 5 standard deviations. The relative branching fraction, with respect to the decay, is measured to be , where the first uncertainty is statistical, the second is systematic, and the third is related to the uncertainties in and .
View Article and Find Full Text PDFPortable Acceleration of CMS Computing Workflows with Coprocessors as a Service.
Comput Softw Big Sci
September 2024
Article Synopsis
- Demand for computing power in major scientific experiments, like the CMS at CERN, is expected to significantly increase over the coming decades.
- The implementation of coprocessors, particularly GPUs, in data processing workflows can enhance performance and efficiency, especially for machine learning tasks.
- The Services for Optimized Network Inference on Coprocessors (SONIC) approach allows for improved use of coprocessors, demonstrating successful integration and acceleration of workflows across various environments without sacrificing throughput.
Background: Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease.
Methods: In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's disease. Participants in whom Parkinson's disease was diagnosed less than 3 years earlier, who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by a 2-month washout period.
Article Synopsis
- The study explored the potential of bumetanide, a medication aimed at enhancing motor symptoms in Parkinson's disease by targeting GABA-ergic cells.
- It involved 44 participants in a 4-month trial comparing bumetanide to a placebo in conjunction with levodopa treatment.
- The results showed no significant improvement in motor symptoms between bumetanide and placebo groups, and bumetanide was poorly tolerated despite no major safety concerns.